Complejo Hospitalario de Toledo -ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

2020

  1. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10

2019

  1. Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients

    Frontiers in Pharmacology, Vol. 10

2017

  1. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

    PLoS ONE, Vol. 12, Núm. 7

2015

  1. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211

  2. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation

    Leukemia, Vol. 28, Núm. 6, pp. 1334-1340

2013

  1. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

    British Journal of Haematology, Vol. 161, Núm. 5, pp. 667-676

  2. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera

    Molecular Cancer, Vol. 12, Núm. 1

2011

  1. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

    Annals of Hematology, Vol. 90, Núm. 8, pp. 939-946

  2. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation

    Journal of Clinical Pathology, Vol. 64, Núm. 11, pp. 1010-1013

  3. Malaria hidden in a patient with diffuse large-B-cell lymphoma and sickle-cell trait

    Journal of Clinical Microbiology, Vol. 49, Núm. 12, pp. 4401-4404

2006

  1. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach

    Leukemia, Vol. 20, Núm. 6, pp. 1047-1054